CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

18 Dec 2023 16:53:03 By Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

14 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

08 Nov 2023 07:00:03 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

03 Nov 2023 12:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

30 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

10 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

09 Aug 2023 07:00:51 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

25 May 2023 17:00:26 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

26 Apr 2023 10:08:32 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

20 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

27 Mar 2023 07:00:06 By Nasdaq GlobeNewswire

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

14 Mar 2023 16:35:18 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

09 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

27 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

13 Feb 2023 19:00:00 By Nasdaq GlobeNewswire